ArticleFrontiers in pharmacology2020
Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Cannabidiol for Mucosal Diseases: Therapeutic Potential and Advanced Delivery Strategies.Pharmaceutics · 2026Review
- Cannabinoids and alcohol co-exposure modulate pathogen-induced pulmonary immune responses.Frontiers in immunology · 2025Article
- Interrelated involvement of the endocannabinoid/endovanilloid (TRPV1) systems and epigenetic processes in anxiety- and working memory impairment-related behavioural effects of nicotine as a stressor.Addiction biology · 2024Article
- Immunomodulatory effects of cannabinoids against viral infections: a review of its potential use in SARS-CoV2 infection.Virusdisease · 2024Review
- Impacts of Inflammatory Cytokines Variants on Systemic Inflammatory Profile and COVID-19 Severity.Journal of epidemiology and global health · 2024Article
- Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders.International journal of molecular sciences · 2024Review
- Case report: Cannabinoid therapy for discoid lupus erythematosus in a dog.Frontiers in veterinary science · 2024Article
- Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases.Cells · 2023Review
- Resveratrol attenuates staphylococcal enterotoxin B-activated immune cell metabolismFrontiers in pharmacology · 2023Article
- Cannabinoids as Emergent Therapy Against COVID-19.Cannabis and cannabinoid research · 2022Review
- Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein.Life sciences · 2022Article
- Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection.International journal of molecular sciences · 2022Review
- Review
- Cannabidiol and SARS-CoV-2 Infection.Frontiers in immunology · 2022Article
- Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line.Phytotherapy research : PTR · 2021Article
- Article
- The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation.Molecules (Basel, Switzerland) · 2021Review
- Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019.Frontiers in pharmacology · 2021Article
- Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?Turkish journal of biology = Turk biyoloji dergisi · 2021Article
- β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19.Frontiers in pharmacology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2. A significant proportion of COVID-19 patients develop Acute Respiratory Distress Syndrome (ARDS) resulting from hyperactivation of the immune system and cytokine storm, which leads to respiratory and multi-organ failure, and death. Currently, there are no effective treatments against hyperimmune syndrome and ARDS. We propose that because immune cells express cannabinoid receptors and their agonists are known to exhibit potent anti-inflammatory activity, targeting cannabinoid receptors, and endocannabinoids deserve intense investigation as a novel approach to treat systemic inflammation, cytokine storm, and ARDS in patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.